August 2017, Vol 7, No 8

Since President Donald J. Trump was sworn into office, there has been much concern over the impact that his administration may have on the FDA. In fact, many predicted that President Trump’s victory would be a “game changer” for the FDA. Read More ›

Cancer drug costs are escalating at an even faster rate, at least in part because of accelerated new approvals by the FDA and higher drug unit costs. Read More ›

The number one stressor for patients with cancer is no longer the fear of dying from their disease; rather, it is fear of their financial obligations because of treatment, said Dan Sherman, MA, LPC, Founder and President, the NaVectis Group, at the 2017 Quality Care Symposium. Read More ›

Movement on the American Health Care Act may continue, and the evolution of the Affordable Care Act (ACA) is not known, said Elizabeth Carpenter, Senior Vice President, Avalere Health, at the 2017 Association of Community Cancer Centers meeting. Read More ›

With cancer care costs on the rise, attaining value-based care—curbing costs while maintaining or improving the quality of care—is becoming a high priority. Alternative payment models are increasingly holding practices accountable for the quality of care that they provide, as well as their use of resources, by requiring that practices report on various quality measures. Read More ›

The cost of cancer drugs has increased exponentially over the past decade, straining the healthcare system and patients’ ability to pay for them. Pharmaceutical manufacturers continue to increase drug prices through packaging maneuvers and the use of artificial expiration dates, and as a result, some old drugs “in new clothing” remain expensive. Read More ›

Read More ›

A brief overview of cancer therapies approved by the FDA between June 1, 2017, and July 30, 2017. Read More ›

Read More ›

Read More ›